Detalhe da pesquisa
1.
Prominent tauopathy and intracellular ß-amyloid accumulation triggered by genetic deletion of cathepsin D: implications for Alzheimer disease pathogenesis.
Alzheimers Res Ther
; 16(1): 70, 2024 Apr 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38575959
2.
Prominent tauopathy and intracellular ß-amyloid accumulation triggered by genetic deletion of cathepsin D: Implications for Alzheimer disease pathogenesis.
Res Sq
; 2023 Oct 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-37961253
3.
Cathepsin D regulates cerebral Aß42/40 ratios via differential degradation of Aß42 and Aß40.
Alzheimers Res Ther
; 12(1): 80, 2020 07 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32631408
4.
Selective modulation of amyloid-beta peptide degradation by flurbiprofen, fenofibrate, and related compounds regulates Abeta levels.
J Neurochem
; 111(3): 683-95, 2009 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-19702658
5.
NO-flurbiprofen reduces amyloid-beta, is neuroprotective in cell culture, and enhances cognition in response to cholinergic blockade.
J Neurochem
; 111(3): 766-76, 2009 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-19702655
6.
Molecular modeling, synthesis, and activity studies of novel biaryl and fused-ring BACE1 inhibitors.
Bioorg Med Chem Lett
; 19(1): 264-74, 2009 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19013792
7.
Anti-inflammatory, antiproliferative, and cytoprotective activity of NO chimera nitrates of use in cancer chemoprevention.
Mol Pharmacol
; 74(5): 1381-91, 2008 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-18676677
8.
Nitrates and NO-NSAIDs in cancer chemoprevention and therapy: in vitro evidence querying the NO donor functionality.
Nitric Oxide
; 19(2): 115-24, 2008 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-18485921
9.
Age and its association with low insulin and high amyloid-ß peptides in blood.
J Alzheimers Dis
; 49(1): 129-37, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26444783
10.
Selective Targeting of Extracellular Insulin-Degrading Enzyme by Quasi-Irreversible Thiol-Modifying Inhibitors.
ACS Chem Biol
; 10(12): 2716-24, 2015 Dec 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-26398879
11.
Optimization of peptide hydroxamate inhibitors of insulin-degrading enzyme reveals marked substrate-selectivity.
J Med Chem
; 56(6): 2246-55, 2013 Mar 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-23437776
12.
LRRTM3 interacts with APP and BACE1 and has variants associating with late-onset Alzheimer's disease (LOAD).
PLoS One
; 8(6): e64164, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23750206
13.
Identification of BACE2 as an avid ß-amyloid-degrading protease.
Mol Neurodegener
; 7: 46, 2012 Sep 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-22986058
14.
Characterization of insulin degrading enzyme and other amyloid-ß degrading proteases in human serum: a role in Alzheimer's disease?
J Alzheimers Dis
; 29(2): 329-40, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22232014
15.
Deletion of insulin-degrading enzyme elicits antipodal, age-dependent effects on glucose and insulin tolerance.
PLoS One
; 6(6): e20818, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-21695259
16.
Designed inhibitors of insulin-degrading enzyme regulate the catabolism and activity of insulin.
PLoS One
; 5(5): e10504, 2010 May 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-20498699